Anna Skaletskaya

2.0k total citations
22 papers, 1.6k citations indexed

About

Anna Skaletskaya is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Anna Skaletskaya has authored 22 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Anna Skaletskaya's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (7 papers) and Cytomegalovirus and herpesvirus research (7 papers). Anna Skaletskaya is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (7 papers) and Cytomegalovirus and herpesvirus research (7 papers). Anna Skaletskaya collaborates with scholars based in United States and France. Anna Skaletskaya's co-authors include Victor S. Goldmacher, Laura M. Bartle, Edward S. Mocarski, Thomas Chittenden, A. Louise McCormick, Peter U. Park, Nancy Kedersha, Robert J. Lutz, Carol A. Vater and Jiawen Han and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Anna Skaletskaya

22 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Skaletskaya United States	12	908	655	467	315	258	22	1.6k
Monique Gannagé Switzerland	21	776 0.9×	397 0.6×	700 1.5×	122 0.4×	235 0.9×	30	1.5k
Margret Müller Germany	8	312 0.3×	399 0.6×	492 1.1×	78 0.2×	166 0.6×	10	870
Casper Paludan United States	8	630 0.7×	260 0.4×	921 2.0×	110 0.3×	351 1.4×	9	1.4k
Jessica M. Boname United Kingdom	21	1.0k 1.1×	547 0.8×	799 1.7×	146 0.5×	455 1.8×	25	1.8k
Mélanie Charmoy Switzerland	18	439 0.5×	278 0.4×	1.1k 2.4×	173 0.5×	544 2.1×	23	1.9k
Shawn A. Motyka United States	13	457 0.5×	608 0.9×	446 1.0×	65 0.2×	72 0.3×	16	1.2k
Craig M. Story United States	12	299 0.3×	631 1.0×	603 1.3×	48 0.2×	98 0.4×	15	1.5k
Pedro Paz United States	13	348 0.4×	559 0.9×	384 0.8×	76 0.2×	92 0.4×	16	1.0k
Peter Lischka Germany	22	1.9k 2.0×	484 0.7×	193 0.4×	356 1.1×	467 1.8×	34	2.3k

Countries citing papers authored by Anna Skaletskaya

Since Specialization

Citations

This map shows the geographic impact of Anna Skaletskaya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Skaletskaya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Skaletskaya more than expected).

Fields of papers citing papers by Anna Skaletskaya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Skaletskaya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Skaletskaya. The network helps show where Anna Skaletskaya may publish in the future.

Co-authorship network of co-authors of Anna Skaletskaya

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Skaletskaya. A scholar is included among the top collaborators of Anna Skaletskaya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Skaletskaya. Anna Skaletskaya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Palacino, James, Pedro Lee, Yeonjoon Kim, et al.. (2023). Abstract 2700: ORM-6151: A first-in-class CD33-antibody enabled GSPT1 degrader for AML. Cancer Research. 83(7_Supplement). 2700–2700. 5 indexed citations

Kim, Yeonjoon, Wesley P. Wong, Olaf Christensen, et al.. (2023). Abstract 2118: Development of RNAscope multiplex-based assay for exploratory pharmacodynamic biomarkers assessment in breast cancer patients from Phase I clinical trial of ORM-5029, a potent GSPT1 degrader. Cancer Research. 83(7_Supplement). 2118–2118. 1 indexed citations

Palacino, James, Yong Yi, Anna Skaletskaya, et al.. (2022). Abstract 3933: ORM-5029: A first-in-class targeted protein degradation therapy using antibody neodegrader conjugate (AnDC) for HER2-expressing breast cancer. Cancer Research. 82(12_Supplement). 3933–3933. 19 indexed citations

Palacino, James, Pedro Lee, Yeonjoon Kim, et al.. (2022). ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML. Blood. 140(Supplement 1). 3061–3062. 14 indexed citations

Qiu, Qifeng, Jose F. Ponte, Leanne Lanieri, et al.. (2019). Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing. ACS Medicinal Chemistry Letters. 10(10). 1393–1399. 18 indexed citations

Widdison, Wayne C., Jose F. Ponte, Leanne Lanieri, et al.. (2017). Abstract 2186: Peptide-cleavable maytansinoid (ADCs) induce high bystander killing leading to improved anti-tumor activity in vivo. Cancer Research. 77(13_Supplement). 2186–2186. 1 indexed citations

Deckert, Jutta, Marie-Cécile Wetzel, Laura M. Bartle, et al.. (2014). SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies. Clinical Cancer Research. 20(17). 4574–4583. 245 indexed citations

Setiady, Yulius Y., Ling Dong, Anna Skaletskaya, et al.. (2014). Abstract 4513: IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors. Cancer Research. 74(19_Supplement). 4513–4513. 3 indexed citations

Chittenden, Thomas, Yulius Y. Setiady, Peter U. Park, et al.. (2013). Abstract 5467: IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.. Cancer Research. 73(8_Supplement). 5467–5467. 3 indexed citations

10.

Setiady, Yulius Y., Peter U. Park, Jose F. Ponte, et al.. (2013). Abstract 5463: Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.. Cancer Research. 73(8_Supplement). 5463–5463. 2 indexed citations

11.

Ponte, Jose F., Yulius Y. Setiady, Ling Dong, et al.. (2013). Abstract 5483: Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck.. Cancer Research. 73(8_Supplement). 5483–5483. 1 indexed citations

12.

Setiady, Yulius Y., Anna Skaletskaya, Jennifer A. Coccia, et al.. (2011). Abstract 4564: huHER3-8, a novel humanized anti-HER3 antibody that inhibits exogeneous ligand-independent proliferation of tumor cells. Cancer Research. 71(8_Supplement). 4564–4564. 4 indexed citations

13.

Arnoult, Damien, et al.. (2008). The murine cytomegalovirus cell death suppressor m38.5 binds Bax and blocks Bax-mediated mitochondrial outer membrane permeabilization. APOPTOSIS. 13(9). 1100–1110. 33 indexed citations

14.

Park, Peter U., Véronique Blanc, Jutta Deckert, et al.. (2008). SAR650984: A Potent Anti-CD38 Therapeutic Antibody with Three Mechanisms of Action (Apoptosis, ADCC, CDC) for Hematological Malignancies. Blood. 112(11). 2756–2756. 3 indexed citations

15.

Arnoult, Damien, Laura M. Bartle, Anna Skaletskaya, et al.. (2004). Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proceedings of the National Academy of Sciences. 101(21). 7988–7993. 165 indexed citations

16.

Poncet, Delphine, Nathanaël Larochette, Anne‐Laure Pauleau, et al.. (2004). An Anti-apoptotic Viral Protein That Recruits Bax to Mitochondria. Journal of Biological Chemistry. 279(21). 22605–22614. 106 indexed citations

17.

McCormick, A. Louise, Anna Skaletskaya, Peter A. Barry, Edward S. Mocarski, & Victor S. Goldmacher. (2003). Differential function and expression of the viral inhibitor of caspase 8-induced apoptosis (vICA) and the viral mitochondria-localized inhibitor of apoptosis (vMIA) cell death suppressors conserved in primate and rodent cytomegaloviruses. Virology. 316(2). 221–233. 114 indexed citations

18.

Skaletskaya, Anna, Laura M. Bartle, Thomas Chittenden, et al.. (2001). A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proceedings of the National Academy of Sciences. 98(14). 7829–7834. 351 indexed citations

19.

Hayajneh, Wail, Anamaris M. Colberg‐Poley, Anna Skaletskaya, et al.. (2001). The Sequence and Antiapoptotic Functional Domains of the Human Cytomegalovirus UL37 Exon 1 Immediate Early Protein Are Conserved in Multiple Primary Strains. Virology. 279(1). 233–240. 79 indexed citations

20.

Goldmacher, Victor S., Laura M. Bartle, Anna Skaletskaya, et al.. (1999). A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proceedings of the National Academy of Sciences. 96(22). 12536–12541. 354 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact